Antimicrobials Working Group

Antimicrobials Working Group AWG utilizes collective power to improve the regulatory, investment, and commercial environment for emerging antimicrobial drug and diagnostics companies.

The Antimicrobials Working Group (AWG) was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging antimicrobials and diagnostics companies. Today, The Antimicrobials Working Group is comprised of thirteen emerging antimicrobial companies. In seven years of work, we have narrowed our focus onto enhanced reimbursement, expedited approval pathways, and sound stewardship measures. The emergence of multi-drug resistant bacteria presents a global public health crisis that demands new antimicrobials and diagnostic devices, yet the number of companies in the United States investing in research and development is dwindling due to lack of attractiveness for investment in the sector. AWG engages with key Congressional offices to help create policies and legislation that spur the development of life-saving antimicrobials and diagnostic devices through appropriate regulatory flexibility; fair and adequate reimbursement policies; and establishing a favorable investment climate to develop antimicrobial therapies and diagnostic devices.

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Con...
09/04/2025

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations…...

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
08/27/2025

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025

JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines…...

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadersh...
08/07/2025

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

CorMedix to pay Melinta $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders

06/30/2025

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth https://bit.ly/4kA7x57

06/25/2025

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence https://bit.ly/4np8tvM

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
06/17/2025

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

IDSA Clinical Infectious Diseases; Emergence and spread of Clostridioides difficile Isolates with Reduced Fidaxomicin Susceptibility in an Acute Care Hospital

06/11/2025

Iterum Therapeutics Announces Partnership for Commercialization Services

Download as PDF June 11, 2025 U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iteru...

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership...
06/09/2025

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

IDSA Clinical Infectious Diseases; Emergence and spread of Clostridioides difficile Isolates with Reduced Fidaxomicin Susceptibility in an Acute Care Hospital

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
05/28/2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold Resumption of dosing in this study triggers a $10M…...

05/19/2025

Iterum Therapeutics Announces Extension of Term of Promissory Note

Download as PDF May 19, 2025 DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both c...

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
04/28/2025

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

IDSA Clinical Infectious Diseases; Emergence and spread of Clostridioides difficile Isolates with Reduced Fidaxomicin Susceptibility in an Acute Care Hospital

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance...
04/14/2025

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Download as PDF April 14, 2025 DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings,....

Address

2200 Pennsylvania Avenue NW, 4th Floor East
Washington D.C., DC
20037

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm
Saturday 9am - 5pm
Sunday 12am - 2pm

Telephone

(202) 803-4214

Website

Alerts

Be the first to know and let us send you an email when Antimicrobials Working Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Antimicrobials Working Group:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram